Clinical Trials - Tuberculosis and HIV
-
The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)
Study Location: India
Eligibility: Pediatrics
Enrollment: Open
-
Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)
Study Location: BaltimoreIndia
Eligibility: Adults, adolescents
Enrollment: Open
-
P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-Infected and Uninfected Children with MDR-TB
Study Location: India
Eligibility: HIV-infected and HIV-uninfected infants, children, and adolescents less than 18 years of age with confirmed or probable MDR-TB.
Enrollment: Open
-
A5253: Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
Study Location: India
Eligibility: Ages Eligible for Study: 13 Years and older (Child, Adult, Senior) Sexes Eligible for Study: All Accepts...
Enrollment: Closed
-
P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age
Study Location: India
Eligibility: Ages Eligible for Study: 3 Months to 35 Months (Child) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Closed
-
A5290, A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis Treatment with or without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV
Study Location: India
Eligibility: Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Closed
-
A5279, Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-infected Individuals with Latent Tuberculosis Infection
Study Location: India
Eligibility: Ages Eligible for Study: 13 Years and older (Child, Adult, Senior) Sexes Eligible for Study: All Accepts...
Enrollment: Closed
-
NWCS 445: Novel Biomarkers to Shorten TB Treatment NWCS 445: Novel Biomarkers to Shorten TB Treatment: A Substudy of S31/A5349
Study Location: India
Eligibility: Partncipants enrolled in “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized,...
Enrollment: Closed
-
NWCS 414, Evaluation of a Serum Biosignature for Identifying HIV-infected Individuals at Greatest risk for Developing Active TB
Study Location: India
Eligibility: N/A
Enrollment: Closed
-
P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease
Study Location: India
Eligibility: Ages Eligible for Study: up to 18 Years (Child, Adult) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Open
-
P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection
Study Location:
Eligibility: Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: Female Accepts...
Enrollment: Closed
-
NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants to Study the Exit from Latent TB Infection and Death: A Supplemental Proposal for A5274
Study Location: India
Eligibility:
Enrollment: Closed
-
A5349: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial (TBTC S31)
Study Location: India
Eligibility: Ages Eligible for Study: 12 Years and older (Child, Adult, Senior) Genders Eligible for Study: Both Accepts...
Enrollment: Closed
-
A5300/P2003: PHOENIx Feasibility Study
Study Location: India
Eligibility: Feasibility Study; N/A
Enrollment: Closed
-
A5274: REMEMBER, Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens
Study Location: India
Eligibility: Participating sites must have a regional TB incidence (i.e., the TB incidence within the site’s expected catchment area)...
Enrollment: Closed
-
P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
Study Location: India
Eligibility: Mother/infant pairs: HIV-infected pregnant women ≥ 14 weeks through ≤ 34 weeks (34 weeks, 6 days) gestation.
Enrollment: Closed